Refreshing results…
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
Download from www.ncbi.nlm.nih.govClinical trial end points relevant to patients and society for rare cancers
Download from www.researchgate.netMissing publications? Search for publications with a matching author name.